Drug Evaluation Committee Presentation slides "Efforts of the pharmaceutical industry to promote utilization of RMP/RMP materials" (July 5, 2025, 27th Annual Meeting of the Japanese Society for Pharmaceutical Informatics)
Pharmacovigilance Subcommittee
November 2025
This document consists of lecture slides at the following symposium.
The 27th Annual Meeting and Annual Conference of the Japanese Society for Drug Informatics
Symposium 5: Exploring the Use of Risk Minimization Materials Associated with RMPs - From the Perspectives of Insurance Pharmacies and Pharmaceutical Companies
According to the revision of medical fees in FY2024, additional fee for specific drug management guidance can be calculated when safety-related explanations are given to patients using materials prepared and distributed as additional risk minimization activities for RMPs (RMP materials). According to the results of a survey conducted by Nexway in May 2025 among insurance pharmacy pharmacists, 78% of all facilities (including those planning to use RMPs) are utilizing RMPs, indicating that interest in RMPs is growing.
This symposium discussed the use of risk minimization materials associated with RMPs from the perspectives of insurance pharmacies and pharmaceutical companies. In this symposium, the speaker, from the standpoint of the pharmaceutical industry, discussed efforts to promote the utilization of RMPs/RMP materials, as well as future issues and proposals for solutions.
Deliverables of the Drug Evaluation Committee Return to list of all deliverables